Biotech firm Dyax (NASDAQ:[[ticker:DYAX]]), based in Cambridge, MA, says that it has struck an exclusive license deal with French drug firm Fovea Pharmaceuticals to develop a version of Dyax’s lead drug ecallantide for eye diseases. Separately, Dyax is pursuing U.S. approval of ecallantide for a rare blood disease called hereditary angioedema (HAE). Last week an FDA panel recommended approval of the protein drug for HAE, and the agency is expected to decide whether to approve the drug by March 23.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
